25,684 Shares in Laboratory Co. of America Holdings (NYSE:LH) Acquired by International Assets Investment Management LLC

International Assets Investment Management LLC purchased a new stake in Laboratory Co. of America Holdings (NYSE:LH) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 25,684 shares of the medical research company’s stock, valued at approximately $5,838,000.

A number of other large investors have also recently bought and sold shares of LH. Bleakley Financial Group LLC grew its holdings in shares of Laboratory Co. of America by 2.8% in the 4th quarter. Bleakley Financial Group LLC now owns 2,310 shares of the medical research company’s stock worth $525,000 after purchasing an additional 64 shares during the last quarter. Equitable Trust Co. lifted its position in shares of Laboratory Co. of America by 15.2% during the fourth quarter. Equitable Trust Co. now owns 131,242 shares of the medical research company’s stock worth $29,830,000 after purchasing an additional 17,298 shares in the last quarter. Tritonpoint Wealth LLC acquired a new position in shares of Laboratory Co. of America during the fourth quarter valued at $2,635,000. Alpine Woods Capital Investors LLC lifted its position in Laboratory Co. of America by 0.3% during the 4th quarter. Alpine Woods Capital Investors LLC now owns 22,998 shares of the medical research company’s stock valued at $5,227,000 after purchasing an additional 70 shares during the period. Finally, Tempus Wealth Planning LLC boosted its stake in Laboratory Co. of America by 9.0% in the fourth quarter. Tempus Wealth Planning LLC now owns 1,484 shares of the medical research company’s stock valued at $337,000 after acquiring an additional 122 shares during the last quarter. 95.94% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

LH has been the subject of a number of analyst reports. Leerink Partnrs restated an “outperform” rating on shares of Laboratory Co. of America in a report on Monday, February 26th. Truist Financial lowered their price target on Laboratory Co. of America from $270.00 to $255.00 and set a “buy” rating for the company in a report on Friday, April 26th. TheStreet cut Laboratory Co. of America from a “b-” rating to a “c+” rating in a report on Thursday, February 15th. SVB Leerink assumed coverage on Laboratory Co. of America in a research note on Monday, February 26th. They set an “outperform” rating and a $260.00 target price for the company. Finally, Barclays reduced their price target on shares of Laboratory Co. of America from $234.00 to $213.00 and set an “equal weight” rating for the company in a report on Friday, April 26th. Four analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $243.14.

Laboratory Co. of America Stock Up 0.2 %

LH stock opened at $201.50 on Wednesday. The business’s 50 day simple moving average is $209.55 and its 200 day simple moving average is $214.89. Laboratory Co. of America Holdings has a 1-year low of $174.20 and a 1-year high of $234.09. The firm has a market capitalization of $16.99 billion, a PE ratio of 40.54, a PEG ratio of 1.51 and a beta of 1.02. The company has a current ratio of 0.88, a quick ratio of 0.76 and a debt-to-equity ratio of 0.39.

Laboratory Co. of America (NYSE:LH) last issued its quarterly earnings data on Thursday, April 25th. The medical research company reported $3.68 earnings per share for the quarter, beating the consensus estimate of $3.48 by $0.20. The company had revenue of $3.18 billion for the quarter, compared to analyst estimates of $3.12 billion. Laboratory Co. of America had a net margin of 3.52% and a return on equity of 14.68%. The company’s revenue was up 4.6% on a year-over-year basis. During the same period in the prior year, the firm earned $3.82 earnings per share. As a group, research analysts anticipate that Laboratory Co. of America Holdings will post 14.87 EPS for the current year.

Laboratory Co. of America Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 12th. Stockholders of record on Tuesday, May 28th will be given a $0.72 dividend. This represents a $2.88 annualized dividend and a dividend yield of 1.43%. The ex-dividend date of this dividend is Tuesday, May 28th. Laboratory Co. of America’s payout ratio is 57.95%.

Insider Transactions at Laboratory Co. of America

In related news, Director Kerrii B. Anderson sold 250 shares of the business’s stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $200.10, for a total value of $50,025.00. Following the completion of the sale, the director now directly owns 15,722 shares in the company, valued at approximately $3,145,972.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CFO Glenn A. Eisenberg sold 34,504 shares of the firm’s stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $215.97, for a total transaction of $7,451,828.88. Following the transaction, the chief financial officer now directly owns 23,595 shares of the company’s stock, valued at $5,095,812.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Kerrii B. Anderson sold 250 shares of the business’s stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $200.10, for a total value of $50,025.00. Following the completion of the sale, the director now owns 15,722 shares of the company’s stock, valued at $3,145,972.20. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 57,244 shares of company stock worth $12,360,478. Company insiders own 0.85% of the company’s stock.

About Laboratory Co. of America

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS).